Combivent Respimat Asthma Inhalers

In May 2019, a class-action lawsuit was filed against Boehringer Ingelheim Pharmaceuticals for allegedly deceptively marketing that the Combivent Respimat asthma inhaler will provide 120 doses when, according to plaintiffs, the inhaler contains far fewer dosages, sometimes less than half the advertised amount. (Ignacuinos et al v. Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-672, D. CT.)

Print Friendly, PDF & Email


Leave a Reply

Back to Top ↑
  • Search Class-Action Tracker

  • Recent Class Actions

  • The Class-Action Tracker is intended to notify consumers about false advertising class-action lawsuits filed around the country, but does not necessarily reflect’s opinion with respect to the lawsuits or disposition of the cases

  • Sign Up for E-mail Updates